Novartis offers to acquire CellforCure1 Jan 2019
Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.
Novartis has announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest CDMOs producing cell and gene therapies in Europe.
Under the proposed agreement, Novartis would acquire the share capital of CellforCure from LFB including the cell and gene manufacturing facility located in Les Ulis and the related adjacent land. If the offer is accepted, CellforCure would become a wholly owned Novartis manufacturing site, joining the network of cell and gene therapy sites including Morris Plains, New Jersey, USA and Stein, Switzerland, where construction continues to progress as planned.
In July 2018, Novartis signed an agreement with CellforCure to produce CAR-T cell therapies including Kymriah (tisagenlecleucel), the first CAR-T cell therapy approved by the FDA and indicated for two distinct, difficult-to-treat cancers in the US, European Union, Switzerland, Canada and Australia. Novartis and CellforCure have successfully completed technology transfer and Kymriah clinical supply production is expected to begin by mid-2019. The proposed acquisition of CellforCure is another example of continued commitment by Novartis to investing in cell and gene therapies as well as in France.
Novartis has made several steps recently to strengthen and expand its cell and gene manufacturing, including signing a strategic licensing, collaboration and share purchase agreement with Cellular Biomedicine Group (CBMG) to manufacture and supply Kymriah in China; expanding an alliance with the Fraunhofer Institute in Germany to support manufacturing for clinical trials and post-approval manufacturing; and a contract manufacturing collaboration in Japan.
Novartis Global Head of Technical Operations Steffen Lang said: "The proposed acquisition of CellforCure is another strategic step in our pursuit of additional manufacturing capacity to make our transformational CAR-T cell therapy Kymriah available to more patients in need around the world. If completed, this acquisition also would potentially increase manufacturing capacity for other cell and gene therapies in the Novartis pipeline. We are excited about the possibility of adding the significant experience of CellforCure to our existing leadership in pioneering research, development and supply of cell and gene therapies."
New HCP Kit for automated impurity analysis of biotherapeutics
21 Jun 2019
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows.Read more
Sanofi and Google to develop new healthcare Innovation Lab
20 Jun 2019
Collaboration aims to change how Sanofi develops new treatments and will focus on to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.Read more
Catalent to purchase BMS manufacturing facility
19 Jun 2019
Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Colorcon launches Opadry Enteric for use with hydro-alcoholic media
17 Jun 2019
A fully formulated one-step system providing simple preparation and ease-of-use for film coating.Read more
SenzaGen granted its first patent for GARD potency biomarker test
16 Jun 2019
Company can now offer an animal-free test method to quantify the strength of an allergenic effect.Read more
Affordable measles and rubella vaccines using NevoLine manufacturing platform
14 Jun 2019
Univercells' propriety bioproduction platform has already proven success.Read more
Leaf Expression Systems launches first line of Hypertrans research products
13 Jun 2019
Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.Read more
Clinical supply milestone reached for triple-negative breast cancer treatment
12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.Read more
Combining IT and OT software to solve manufacturing’s most frequent challenges
11 Jun 2019
PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation